Xiangyu Wang

Statistics

Publications

Citations

1.6K

H-Index

Active since

2012

Affiliations

Chinese Academy of Medical Sciences & Peking Union Medical College(Current)

Harvard University

Massachusetts General Hospital

Huazhong University of Science and Technology

Tongji Hospital

Xiangyu Wang is an author at Chinese Academy of Medical Sciences & Peking Union Medical College specializing in oncology, breast cancer prognosis, and medicine.

ORCID

Publications per year

2012–2023

Publications

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

Nanoparticle drug delivery systems and their applications as targeted therapies for triple negative breast cancer

Xiangyi Kong, Yihang Qi, Xiangyu Wang et al. · Progress in Materials Science · 2023 · 147 citations

Pharmacy, Oncology, Pharmaceutics +16

Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator

Li Chen, Ping Bai, Xiangyi Kong et al. · Frontiers in Cell and Developmental Biology · 2021 · 128 citations · Full text

Agriculture, Nutrition, Oncology +17

LINC01355 suppresses breast cancer growth through FOXO3-mediated transcriptional repression of CCND1

Bolun Ai, Xiangyi Kong, Xiangyu Wang et al. · Cell Death and Disease · 2019 · 77 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Comprehensive Analysis of the Expressionand Prognosis for TDO2 in Breast Cancer

Qiang Liu, Jie Zhai, Xiangyi Kong et al. · Molecular Therapy — Oncolytics · 2020 · 62 citations · Full text

Medicine, Immunology, Oncology +17

1–5 of 22